<DOC>
	<DOCNO>NCT02408042</DOCNO>
	<brief_summary>To determine recommended phase 2 dose chemotherapy combination Pembrolizumab subject advanced lymphoma determine complete response rate .</brief_summary>
	<brief_title>Study Pembrolizumab With Chemotherapy Patients With Advanced Lymphoma ( PembroHeme )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patient least 18 year old definitive histologically cytologically confirm : classical Hodgkin lymphoma ( HL ) diffuse large BCell lymphoma ( DLBCL ) nonHodgkin lymphoma ( NHL ) . 2 . Patient one metastatic lesion &gt; 1.5 cm define lymphoma response criterion PETCT scan . If CT scan need clarification finding PETCT may do additionally . Tumor site consider measureable must receive prior radiation therapy . 3 . Patients enrol one treatment arm trial . 4 . The investigator select appropriate treatment arm patient follow requirement : ( ) Patients prior progression intolerance single agent chemotherapy enrol arm single agent chemotherapy plus pembro ( b ) The chemotherapy arm select must consider standard care list www.nccn.org cancer type . 5 . Have recover acute toxicity prior treatment : &gt; 3 week must elapse since receive investigational agent . &gt; 2 week must elapse since receive radiotherapy , ≥ 3 week 5 halflives whichever shorter treatment cytotoxic biologic agent ( ≥ 6 week mitomycin nitrosoureas ) . Chronic treatment noninvestigational gonadotropinreleasing hormone analog hormonal supportive care permit . 6 . Patient adequate biological parameter demonstrate follow blood count time screening : 7 . Absolute neutrophil count ( ANC ) &gt; 1000/ microliter , platelet count ≥ 75,000/ microliter , hemoglobin ≥ 9 g/dL . Subject give pack red blood cell transfusion . 8 . Calculated creatinine clearance &gt; 50 ml/min CockroftGault equation , total bilirubin 1.5 time upper limit normal ( ULN ) range , AST/ALT ≤ 3 time upper limit normal ( ULN ) range . 9 . Thyroid stimulate hormone ( TSH ) within institutional normal limit . If TSH upper limit normal range , free T4 within institutional normal limit acceptable . 10 . At least 100 day must elapse subject prior autologous transplant . 11 . Resolution prior systemic therapy nonhematologic AE grade ≤ 2 ( except alopecia correctable electrolyte abnormality supplementation ) 12 . Patient Karnofsky performance status ( KPS ) ≥ 60 . 13 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable contraceptive method ( abstinence , oral contraceptive double barrier method ) duration study 4 month follow last dose Pembrolizumab , brentuximab vedotin , 2 year follow last dose chemotherapy trial , must negative urine serum pregnancy test within 2 week prior begin treatment trial . If female subject female partner male subject become pregnant period patient recommend seek appropriate obstetric care . The study monitoring subject female partner subject pregnancy last dose study drug chemotherapy . 1 . Active clinically serious infection &gt; Grade 2 . 2 . Serious nonhealing wound , ulcer , bone fracture . 3 . Patient known brain metastasis . 4 . Patient myelodysplasia , polycythemia vera , idiopathic thrombocythemia , myelofibrosis , acute leukemia . 5 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 6 . Patient know active infection HIV , hepatitis B , hepatitis C ( patient require tested presence virus prior therapy protocol ) . 7 . Ejection fraction measure less 45 % ( measurement ejection fraction require subject prior anthracycline exposure ) . 8 . Requiring daily corticosteroid dose ≥ 10 mg prednisone equivalent per day . 9 . Patient undergone major surgery , diagnostic surgery ( e.g. , surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Day 1 treatment study . 10 . Patient history allergy hypersensitivity study drug excipients , patient exhibit event outline Contraindication Special Warnings Precautions section product comparator SmPC Prescribing Information . 11 . Patient serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise patient 's safety study data integrity . 12 . Patient receive anticancer therapy participation trial . 13 . Prior treatment Pembrolizumab allow . Prior receipt PD1 inhibitor PDL1 inhibitor allow . 14 . Active prior document autoimmune disease require systemic treatment within past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>